本帖最后由 老马 于 2013-3-13 13:43 编辑
" L; J+ g2 S, v! a" v$ s- |9 O! [! ^
健择（吉西他滨）+顺铂+阿瓦斯汀
5 K/ z, b! f) [9 K Gemzar +Cisplatin + Avastin" X8 x6 o/ B7 ?$ V; i7 w, |
http://annonc.oxfordjournals.org/content/21/9/1804.full
) d1 r/ r" V9 H2 m0 tOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
! a; D! X; X$ t7 EPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& r9 A/ F2 }; fResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 2 D/ J/ C0 C6 m' M- D
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 938)
) Z- A0 y. M/ z# w& @( Q( e华为网盘附件：
+ j4 [4 a2 Y$ Z/ F z【华为网盘】ava.JPG
) [. }* f0 M! c- x _/ C |
显身卡
